https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Curr. Pharm. Des. 2005;11(27):3461-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Curr. Pharm. Des. 2005;11(27):3461-732005-01-01 00:00:002019-02-15 09:19:57Melanoma immunotherapy: past, present, and future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Nutr Cancer 2005;53(2):177-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Nutr Cancer 2005;53(2):177-932005-01-01 00:00:002019-02-15 08:50:23Chemo-immunotherapy of breast cancer using vesiculated alpha-tocopheryl succinate in combination with dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Curr. Pharm. Des. 2005;11(27):3475-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Curr. Pharm. Des. 2005;11(27):3475-832005-01-01 00:00:002019-02-15 08:50:23Immunotherapy and cancer vaccines in the management of breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Nat Clin Pract Urol 2005 Jan;2(1):44-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Nat Clin Pract Urol 2005 Jan;2(1):44-512005-01-01 00:00:002019-02-15 09:24:18Technology Insight: vaccine therapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Methods Mol. Med. 2005;109:127-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Methods Mol. Med. 2005;109:127-362005-01-01 00:00:002019-02-15 08:51:03Dendritic cells in clinical trials for multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Vopr Onkol 2005;51(6):685-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Vopr Onkol 2005;51(6):685-82005-01-01 00:00:002019-02-15 08:53:38[Combined radiotherapy and endovascular x-ray therapy for invasive cancer of the urinary bladder]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / BioDrugs 2005;19(5):289-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / BioDrugs 2005;19(5):289-972005-01-01 00:00:002019-02-15 09:25:42Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Anticancer Res. 2005 Jan-Feb;25(1B):443-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Anticancer Res. 2005 Jan-Feb;25(1B):443-92005-01-01 00:00:002005-01-01 00:00:00Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Immunol. Invest. 2005;34(3):245-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Immunol. Invest. 2005;34(3):245-582005-01-01 00:00:002005-01-01 00:00:00Comparison of the anti-tumor effects of various whole-body hyperthermia protocols: correlation with HSP 70 expression and composition of splenic lymphocytes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Strahlenther Onkol 2005 Jan;181(1):35-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Strahlenther Onkol 2005 Jan;181(1):35-412005-01-01 00:00:002019-02-15 10:00:38Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0
